OncoMatch/Clinical Trials/NCT06944106

A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

Is NCT06944106 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies AK112 for pancreatic cancer.

Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalNCT06944106Data as of May 2026

Treatment: AK112 — This trial is a prospective, single-arm, single-center Phase II clinical study aimed at evaluating the efficacy and safety of Ivonescimab combined with the gemcitabine and nab-paclitaxel (AG) regimen as neoadjuvant therapy for borderline resectable pancreatic cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage BORDERLINE RESECTABLE

Borderline resectable disease

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: immunotherapy (anti-pd-1, anti-pd-l1, anti-pd-l2, anti-ctla-4)

Lab requirements

Blood counts

absolute neutrophil count (anc) ≥1.5×10⁹/l, platelets (plt) ≥100×10⁹/l, hemoglobin (hb) ≥90 g/l, white blood cells (wbc) ≥3.0×10⁹/l

Kidney function

serum creatinine (cr) ≤1.5×uln or creatinine clearance ≥60 ml/min (calculated by cockroft-gault formula)

Liver function

alt and ast ≤2.5×uln; total bilirubin ≤1.5×uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify